Please login to the form below

Not currently logged in
Email:
Password:

PR and Med Ed news in brief

Our weekly round up of healthcare PR stories

J&J linked with Olympic sponsorship deal

Speculation is mounting that Johnson & Johnson is set to become a top-tier sponsor of the Olympic Games. The US pharma company is expected to sign a £100m deal with the International Olympic Committee after the completion of the 2006 Winter Games in Turin next February. The deal would allow J&J to use the famous Olympic Rings trademark across all its products and have an exclusive presence at future Games up until at least the London Games in 2012.

Galliard wins GSK Avodart contract

Galliard Healthcare Communications has won the global PR contract for GlaxoSmithKline's (GSK) benign prostatic hyperplasia treatment Avodart. The London-based agency beat off competition from Edelman and Ketchum to replace Fleishman-Hillard, which declined to repitch for the account citing a conflict of interest. Galliard managing director Marika Freris will lead a four-strong team on the account, reporting to GSK's global scientific communications strategy team. GSK is currently investigating Avodart's use in the prevention of prostate cancer, a potentially lucrative market if it succeeds in clinical trials.

2nd September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

] [PR and Med Ed news in brief, Our weekly round up of healthcare PR stories, News Article, , ,] -->

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics